

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for cleaving glycation endproducts or cross-linked proteins in an organism, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

LR-102: 1, 4-benzene-bis[4-methyleneaminophenoxyisobutyric acid]; and

LR-99: 4-[3,5-dichlorophenylureidophenoxyisobutryl]-4-aminobenzoic acid.

2. (Original) The method of claim 1 wherein said compound is 1,4-benzene-bis [4-methyleneaminophenoxyisobutyric acid].

3. (Original) The method of claim 1 wherein said compound is 4-[3,5-dichlorophenylureidophenoxyisobutryl]-4-aminobenzoic acid.

4. (Currently Amended) A method of treating reversing deleterious effects of aging in an organism, ~~wherein said effects are formation of glycation endproducts or protein cross-~~

~~linking~~, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

LR-102: 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid]; and

LR-99: 4-[(3,5-dichlorophenylureidophenoxyisobutryl)]-4-aminobenzoic acid.

5. (Original) The method of claim 4 wherein said compound is 1,4-benzene-bis [4-methyleneaminophenoxyisobutyric acid].

6. (Original) The method of claim 4 wherein said compound is 4- [3,5-dichlorophenylureidophenoxyisobutryl]-4-aminobenzoic acid.

7. (Currently Amended) A method of treating ~~reversing~~ complications resulting from diabetes, ~~wherein said complications result from formation of glycation endproducts or protein cross-linking~~, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said organism wherein said compound is selected from the group consisting of:

LR-102: 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid]; and

LR-99: 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid.

8. (Original) The method of claim 7 wherein said compound is 1,4-benzene-bis-[4-methyleneaminophenoxyisobutyric acid].

9. (Original) The method of claim 7 wherein said compound is 4-[3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid.

10. (Currently Amended) A method of ~~treating slowing disease progression as treatment~~ in a patient having rheumatoid arthritis, Alzheimer's disease, uremia, neurotoxicity, or atherosclerosis ~~by cleaving advanced glycation endproducts or cross-linked proteins~~, wherein said method comprises administering an effective amount of a compound or a pharmaceutically acceptable salt of said compound to said patient wherein said compound is selected from the group consisting of:

LR-102: 1,4-benzene-bis[4-methyleneaminophenoxyisobutyric acid]; and

LR-99: 4-[(3,5-dichlorophenylureidophenoxyisobutyryl)-4-aminobenzoic acid.

11. (Original) The method of claim 10 wherein said compound is 1,4-benzene-bis

4[methyleneaminophenoxyisobutyric acid].

12. (Original) The method of claim 10 wherein said compound is 4-[(3,5-dichlorophenylureidophenoxyisobutyryl]-4-aminobenzoic acid.